Antimicrobial peptides (AMPs) are promising novel antibiotics since they have shown antimicrobial activity against a ... either prior or after binding to the membrane surface, rather than the helical ...

These factors also influence the frequency (number of doses per day) and duration (number of days) of treatment with amoxicillin or penicillin. Typical dosages of amoxicillin and penicillin are: ...

Modern life makes us tired, right? But research from societies in Africa and South America suggests people in the ancient ...

If you've been diagnosed with an environmental Penicillium mold allergy, you might wonder if that means you could have a penicillin allergy or food allergies, too. An environmental mold allergy is ...

Antibiotics are ineffective against viral infections like human metapneumovirus (HMPV). HMPV affects the respiratory system, and antibiotics, designed to target bacteria, won't help. Misusing ...

In tandem, several companies have renewed efforts to discover novel types of antibiotics to replace the declining number of agents ... stage company adopting structure-based drug design of ...

β-Lactams are the most widely employed antibiotics in clinical settings due to their broad efficacy and low toxicity ... In this Mini Review, recent advances in structure-function relationships of ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

aureus. Several new antibiotics such as linezolid, tigecycline and daptomycin, among others, are now available for the management of cSSSI. Other agents are under investigation and should be ...

Industrial approaches do exist for expressing large numbers of proteins to support ... possible that different groups could solve the same structure, it may prove valuable to coordinate target ...

AI models are able to design molecules that don’t even exist in nature. Some have proven effective as snake antivenom.

Iterum Therapeutics PLC (NASDAQ:ITRM) reported its fourth-quarter 2024 financial results, revealing a narrower-than-expected loss. The company posted an actual EPS of -0.12, beating the forecasted EPS ...